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1973Degenerative aortic valve disease resulting in severe stenosis is
the most common form of valvular heart disease in developed
countries (1). Surgical aortic valve replacement (SAVR) re-
mains the therapy of choice formost patients with severe aortic
stenosis, and this therapy is associated with an improvement in
both symptoms and survival (2). A signiﬁcant number of pa-
tients with severe aortic stenosis, however, are not candidates
for SAVR, due to pre-existing comorbidities, frailty,
and disabilities (3). Patients denied surgery have a dismal
prognosis, with an estimated mortality rate of 50% within 1
year after surgical evaluation (4).
Transcatheter aortic valve replacement (TAVR) is an
alternative to SAVR in selected patients with aortic stenosis
(5,6). Balloon-expandable TAVR in patients deemed un-
suitable for surgery reduced 12-month mortality compared
with medical therapy, albeit with a higher 30-day incidence
of major stroke, vascular complication, and paravalvular
regurgitation (4), each of which was associated with late
mortality (4,7). The CoreValve self-expanding transcatheter
bioprosthetic heart valve (Medtronic, Inc., Minneapolis,
Minnesota) has been widely used worldwide (8,9), but a
rigorous, prospective evaluation of this device in patients
recognized to be at an extreme risk for surgery has not been
performed.
The CoreValve Extreme Risk Pivotal Trial evaluated
patients who were deemed to have an extreme risk for SAVR
and were treated with this self-expanding transcatheter heart
valve (THV). Our objective was to evaluate the clinical safety
and efﬁcacy of self-expanding TAVR in patients at extreme
risk for SAVR.Methods
Patient selection. Patients with New York Heart Associ-
ation (NYHA) class II or greater symptoms related to aortic
valve disease were eligible for the trial. Severe aortic stenosis
was deﬁned as an aortic valve area 0.8 cm2 or aortic valve
index 0.5 cm2/m2 and either a mean aortic valve gradient
>40 mm Hg or a peak aortic valve velocity >4.0 m/s at rest
or with a dobutamine stress if the left ventricular ejection
fraction was <50%. Patients were considered at extreme risk
if 2 cardiac surgeons and 1 interventional cardiologist at the
clinical site estimated a 50% or greater risk for mortality or
irreversible morbidity at 30 days with SAVR.
Principal exclusion criteria were an active gastrointestinal
hemorrhage within the prior 3 months, a major stroke within
the prior 6 months, or a life expectancy <1 year due toMedtronic, Inc. Dr. Popma has received research grants from Abbott Vascular,
Abiomed, Boston Scientiﬁc, Cordis, Covidien, eV3, and Medtronic; and serves as an
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sion criteria included an aortic
annular diameter<18mmor>29
mm, moderate to severe or severe
mitral regurgitation, or a dilated
ascending aorta. A complete list of
all inclusion and exclusion criteria
is found in the Online Appendix
(Online Table 1S).
A case summary was created
for each patient that included
comorbidities and independent
imaging review by a central lab-
oratory and was presented by
the clinical site heart team to a
national screening committee
(Online Table 2S). At least 2
senior cardiac surgeons and 1
interventional cardiologist had to
agree that the patient met study
eligibility, risk, and imaging
criteria for the trial.
Study device. The CoreValve
system consists of 3 components: the THV, delivery catheter
system, and compression loading system. The THV com-
prises a self-expanding nitinol frame that supports a trileaﬂet
porcine pericardial valve. The valves available in this report
included those with 23-, 26-, 29-, and 31-mm diameters
treating patients with an annulus range from 18 to 29 mm
(Fig. 1). The inﬂow portion of the frame is designed to
conform to the annulus and to stabilize the frame at the
annular location. The lowest 12 mm of the frame contains a
porcine pericardial skirt to seal the annulus. The valve is
located in a supra-annular position at the waist (constrained
portion) of the valve frame. The outﬂow portion of the valve
frame is constructed to support the valve commissures and
orient the frame to facilitate laminar ﬂow. All valve sizes are
delivered using an 18-F catheter delivery system. The valve
is deployed without rapid pacing and is partially reposi-
tionable until annular contact with the THV is made.
Procedural details. The size of the selected bioprosthesis
was determined based on a pre-enrollment computed to-
mography angiogram. Aspirin 325 mg and clopidogrel
300 to 600 mg were given prior to the procedure. Following
general anesthesia or deep conscious sedation and attain-
ment of arterial access, anticoagulation with intravenous
heparin or bivalirudin was given to achieve an activatedVascular, Medtronic, and St. Jude Medical. Dr. Hughes serves as a consultant and
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Figure 1 CoreValve Transcatheter Heart Valve
The self-expanding nitinol frame serves to anchor the transcatheter heart valve at
the level of the aortic annulus. The supra-annular trileaﬂet porcine pericardial valve
is hand sewn to the nitinol frame.
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1974clotting time of at least 250 s. Through an 18-F sheath,
aortic valvuloplasty was performed using a balloon under-
sized to the aortic annulus and rapid ventricular pacing to a
target systolic pressure <60 mm Hg. The self-expanding
THV was then advanced across the aortic valve. Contrast
injections were performed through a pigtail catheter posi-
tioned in the noncoronary sinus to guide positioning of the
inﬂow portion of the frame 2 to 6 mm inferior to
the noncoronary basal annulus. After valve deployment,
the delivery catheter was removed and valve performance
was evaluated using transthoracic or transesophageal echo-
cardiography, aortography, and invasive measurements of
transaortic valve gradients and left ventricular end-diastolic
pressures. Valve repositioning using a vascular snare,
balloon post-dilation, or placement of an additional bio-
prosthetic valve was used to treat signiﬁcant residual aortic
regurgitation after deployment. The 18-F sheath was then
removed using percutaneous or surgical techniques. Dual
antiplatelet therapy with aspirin 81 mg daily and clopidogrel75 mg daily was recommended for 3 months after the
procedure, followed by aspirin at least 81 mg daily or clo-
pidogrel 75 mg daily indeﬁnitely. In the event that warfarin
was indicated for other reasons, aspirin at least 81 mg daily
and warfarin were administered indeﬁnitely.
Study design. The CoreValve Extreme Risk Pivotal Trial
was a prospective, multicenter, controlled, nonrandomized
single-arm clinical study performed at 41 clinical sites in
the United States (Online Table 3S). The responsible
institutional review boards approved the study protocol, and
written informed consent was obtained from all patients.
The trial was conducted in accordance with the International
Conference on Harmonization, Good Clinical Practice
Guidelines, and the Declaration of Helsinki.
The clinical study was designed and funded by the study
sponsor (Medtronic). The study sponsor was responsible
for selection of the clinical sites, monitoring of the data,
and management of the case report forms and statistical
analyses. An independent clinical events committee (Online
Table 2S) adjudicated all major adverse clinical events. The
data and safety monitoring board was responsible for study
oversight. The CoreValve US steering committee reviewed
the primary manuscript and made the decision to submit the
manuscript for publication.
Analysis populations. The intended treatment population
included all patients accepted by the screening committee
who were then enrolled in the study by the clinical site.
The attempted implant population included patients with
a documented valve implant attempt via an iliofemoral
approach. The attempted implant population was pre-
speciﬁed as the primary analysis group.
A detailed assessment of the patient baseline comorbidities
was performed using the Society for Thoracic Surgery Pre-
dicted Risk of Mortality (STS-PROM) (10), European
System for Cardiac Operative Risk Evaluation (Euro-
SCORE) (10), and Charlson comorbidity index (11). Frailty
markers included a 5-m gait speed test (12) and grip strength
testing (13). Disability was assessed using Katz activities
of daily living (14) and mini-mental test for dementia (15).
Study endpoints. The primary endpoint was the rate of all-
cause mortality or major stroke 12 months after the procedure
in the attempted implant population.Major and minor stroke
were deﬁned using Valve Academic Research Consortium
(VARC)-1 criteria (16) (Online Table 4S). Criteria for major
adverse cardiovascular and cerebral events (MACCE)
comprising all-cause death, myocardial infarction, all stroke,
and reintervention to alter, adjust, or replace a previously
implanted valve, along with additional secondary endpoints,
are found in the Online Appendix (Online Table 4S).
Symptom status was assessed using the NYHA classiﬁcation
system.Device success was deﬁned using theVARC-1 criteria
(Online Table 4S) (16). Procedure success was deﬁned as
device success in the absence of in-hospital MACCE.
Echocardiographic analysis. Serial echocardiograms were
collected at screening, post-procedure (within 24 to 48 h),
hospital discharge, and 1, 6, and 12 months after THV
Figure 2 Study Flow Diagram
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1975implantation and were interpreted by a central laboratory
(Mayo Echocardiography Core Laboratory, Rochester,
Minnesota). Prosthetic valve dysfunction and periprocedural
aortic regurgitation were determined using VARC-1 criteria
(16).
Statistical analysis. For estimation of the rate of death or
major stroke in patients with aortic stenosis at prohibitive
risk for surgery treated with standard therapy, an objective
performance goal (OPG) of 43% for all-cause mortality or
major stroke was determined from 2 sources. A weighted
meta-analysis performed of 7 contemporary balloon aortic
valvuloplasty studies (17–23) yielded a rate of 12-month all-
cause mortality or major stroke of 42.7% (95% conﬁdence
interval: 34.0% to 51.4%). The meta-analysis estimate was
then adjusted based on the lower 95% conﬁdence boundary
of 43% in the standard therapy arm of inoperable patients in
PARTNER (Placement of Aortic Transcatheter Valve
Trial) B (4). The rate of all-cause mortality or major stroke
with TAVR was estimated to be 36.5% (33.0% plus 1 SE of
3.5%) based on the treatment group of the PARTNER B
trial (4).
The study had one primary objective, which was to
demonstrate that the combined all-cause mortality or major
stroke rate at 12 months was <43.0% after treatment with
the self-expanding THV. A sample size of 438 was required
to obtain a 1-sided alpha of 0.025; power ¼ 0.80 and
assumed a 36.5% Kaplan-Meier rate of death or major stroke
for patients treated with the THV in the as-treated popu-
lation. Accounting for an approximate 10% attrition rate, a
total of 506 patients were recruited in the study.
Categorical variables were compared with the use of the
Fisher exact test. Continuous variables were presented as
mean  SD and compared with the use of Student t test.
Kaplan-Meier estimates were used to construct the survival
curves based on all available follow-up for the time-to-event
analysis. All testing used a 2-sided alpha level of 0.05. All
statistical analyses were performed with SAS software,
version 9.2 (SAS Institute, Cary, North Carolina).Results
Patient enrollment. From February 2011 to August 2012,
41 centers in the United States recruited 506 patients for
treatment with the CoreValve THV (Fig. 2). Prior to
treatment, 11 patients exited from the study: 4 patients died,
3 withdrew consent, and 4 were withdrawn by the treating
physicians. An additional 6 patients did not complete the
procedure with iliofemoral access: 4 underwent left subcla-
vian TAVR and 2 underwent direct aortic implantation. All
489 remaining patients were included in the attempted
implant analysis population.
Patient demographics. Patient demographics for the
attempted implant population are in Table 1. Patients were
elderly (83.2  8.7 years), commonly women (52.1%), and
severely symptomatic (NYHA class III or IV 91.8%). The
STS-PROM was 10.3%  5.5% and was >15% in 17.2% ofpatients. A history of atrial ﬁbrillation was present in 46.8%
of patients.
Anatomic factors precluding SAVR are in Table 1. Sig-
niﬁcant comorbidities and frailty indexes are in Table 2.
Using STS criteria, severe lung disease was present in 23.5%
of patients, and home oxygen therapy was used in 29.9% of
patients. A total of 58.7% of patients had severe comor-
bidities using the Charlson comorbidity index. The average
5-m gait speed was >6 s in 84.2% of patients, and the grip
strength was below the age- and sex-matched threshold in
67.7% of patients. Disability assessments prior to the pro-
cedure are in Table 3. Two or more deﬁcits in activities of
daily living were present in 20.7% of patients and 3 or more
deﬁcits were found in 13.9% of patients.
Procedural outcomes. A total of 486 of 489 patients
(99.4%) underwent the THV implantation procedure.
Most patients (94.4%) were given general anesthesia.
Balloon pre-dilation was performed in 478 patients (98.4%),
and post-dilation after the THV implantation was per-
formed in 101 patients (20.8%). The distribution of
implanted valve sizes were 23 mm (2.5%), 26 mm (35.0%),
Table 1 Patient Baseline Demographics (N ¼ 489)
Age, yrs 83.2  8.7
Female 255 (52.1)
NYHA functional class
II 40 (8.2)
III 313 (64.0)
IV 136 (27.8)
STS-PROM 10.3  5.5
<10% 272 (55.6)
10%–15% 133 (27.2)
>15% 84 (17.2)
Logistic EuroSCORE, % 22.6  17.1
Diabetes mellitus 203 (41.5)
Controlled by insulin 90 (18.4)
Creatinine level >2 mg/dl 22 (4.5)
Chronic kidney disease class 4/5 63/484 (13.0)
History of hypertension 441 (90.2)
Peripheral vascular disease 171/486 (35.2)
Prior stroke 67/488 (13.7)
Prior TIA 47/488 (9.6)
Cardiac risk factors
Coronary artery disease 400 (81.8)
Prior coronary artery bypass surgery 193 (39.5)
Prior percutaneous coronary intervention 181 (37.0)
Prior balloon valvuloplasty 100 (20.4)
Pre-existing pacemaker/deﬁbrillator 127 (26.0)
Previous myocardial infarction 151 (30.9)
Congestive heart failure 473 (96.7)
Prior atrial ﬁbrillation/atrial ﬂutter 228/487 (46.8)
Factors unfavorable for surgical aortic valve surgery
Aorta calciﬁcation
Severe 84/488 (17.2)
Porcelain 24/488 (4.9)
Chest wall deformity 27 (5.5)
Hostile mediastinum 58/488 (11.9)
Values are mean  SD, n (%), or n/N (%). Denominator ¼ 489 unless otherwise indicated.
EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; NYHA ¼ New York Heart
Association; STS-PROM ¼ Society for Thoracic Surgery Predicted Risk of Mortality; TIA ¼ transient
ischemic attack.
Table 2 Comorbidities and Frailty (N ¼ 489)
Comorbidities
STS chronic lung disease severity
None 201 (41.1)
Mild 98 (20.0)
Moderate 75 (15.3)
Severe 115 (23.5)
Home oxygen 146 (29.9)
FEV1 <1,000 ml 116 (23.7)
DLCO <50% 109 (22.3)
Liver cirrhosis 15 (3.1)
Connective tissue disease 13/487 (2.7)
Immunosuppressive therapy 62 (12.7)
Charlson comorbidity index 5.3  2.3
None (score ¼ 0) 0 (0.0)
Mild (score ¼ 1 or 2) 41 (8.4)
Moderate (score ¼ 3 or 4) 161 (32.9)
Severe (score ¼ 5) 287 (58.7)
Frailty
Anemia with transfusion 108/473 (22.8)
Body mass index <21 kg/m2 42 (8.6)
Albumin <3.3 g/dl 88/484 (18.2)
Unplanned weight loss 61 (12.5)
Fall in past 6 months 88 (18.0)
5-m gait speed, s, mean  SD (n) 14.8  28.0 (336)
Patients with average >6 s 283/336 (84.2)
Grip strength below threshold (13) 329/486 (67.7)
Values are n (%), n/N (%), or mean  SD.
DLCO ¼ diffusing capacity of lung carbon monoxide; FEV1 ¼ forced expiratory volume in
1 second; other abbreviation as in Table 1.
Table 3 Disability Assessments (N ¼ 489)
Disability Factor
Dementia, based on MMSE score
None (25) 352/488 (72.1)
Mild (21–24) 112/488 (23.0)
Moderate (10–20) 23/488 (4.7)
Severe (<10) 1/488 (0.2)
Does not live independently 135 (27.6)
ADL
Does not bathe independently 106 (21.7)
Does not dress independently 85 (17.4)
Does not toilet independently 44 (9.0)
Does not transfer independently 91 (18.6)
Incontinent 32 (6.5)
Does not feed independently 12 (2.5)
Deﬁcit >2 ADLs 101 (20.7)
Deﬁcit >3 ADLs 68 (13.9)
Values are n/N (%) or n (%).
ADL ¼ activities of daily living; MMSE ¼ mini–mental state examination.
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197629 mm (58.4%), and 31 mm (4.1%). Two or more Core-
Valve THVs were implanted in 17 patients (3.5%). The
average procedure time was 66.1  39.0 min. The median
length of stay was 7 days. The device success rate was
84.6% as deﬁned by VARC-1, and the procedural success
rate was 77.6% (Online Table 5S).
Clinical endpoints. The Kaplan-Meier rate of the primary
endpoint of 12-month all-cause mortality or major stroke
in the attempted implant population was 26.0% with an
upper 2-sided 95% CI of 29.9% (Table 4). The upper 95%
CI was signiﬁcantly lower than the pre-speciﬁed OPG of
43% (p < 0.0001), and therefore this study met its primary
endpoint (Fig. 3). The Kaplan-Meier rates of all-cause
mortality at 30 days and 12 months were 8.4% and 24.3%,
respectively; and the rates of major stroke at 30 days and
12 months were 2.3% and 4.3%, respectively. The causes of
mortality through 12 months are in Online Table 6S. A
permanent pacemaker implantation was required in 104patients (21.6%) by 30 days and 123 patients (26.2%) at 1
year, most often due to atrioventricular block. All MACCE
endpoints for the attempted implant population are reported
in Table 4.
At 12 months, the Kaplan-Meier rate of the primary
endpoint in the intended population was 27.0% (upper 2-
sided 95% CI: 30.9%). The all-cause mortality rate was
Table 4 Clinical Outcomes at 30 Days and 12 Months*
Outcome
30 Days
(N ¼ 489)
12 Months
(N ¼ 489)
Death from any cause or major stroke 48 (9.8) 127 (26.0)
Death
From any cause 41 (8.4) 119 (24.3)
Cardiovascular 41 (8.4) 88 (18.3)
Stroke 19 (4.0) 31 (7.0)
Major 11 (2.3) 19 (4.3)
Minor 9 (1.9) 14 (3.2)
TIA 3 (0.6) 5 (1.1)
MACCE 60 (12.3) 143 (29.2)
Myocardial infarction 6 (1.2) 9 (2.0)
Periprocedural 6 (1.2) 6 (1.2)
Spontaneous 0 (0) 3 (0.7)
Reintervention 5 (1.1) 8 (1.8)
Major or life-threatening bleeding 179 (36.7) 206 (42.8)
Life-threatening or disabling 62 (12.7) 83 (17.6)
Major 121 (24.9) 136 (28.5)
Major vascular complications 40 (8.2) 41 (8.4)
Acute kidney injury 57 (11.8) 57 (11.8)
Cardiogenic shock 13 (2.7) 13 (2.7)
Cardiac perforation 9 (1.8) 9 (1.8)
Device migration 0 1 (0.2)
Device embolization 0 0
Values are n (%). *All percentages are Kaplan–Meier estimates at the speciﬁc time point and thus
do not equal the number of patients divided by the total number in the study group.
MACCE ¼ major adverse cardiovascular and cerebrovascular event(s); other abbreviation as in
Table 1.
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197724.6% and the major stroke rate was 4.6% in the intended
population.
NYHA class improved signiﬁcantly from baseline to
12-month follow-up (D 1.6  0.9; p < 0.0001). At baseline,
the majority of patients (91.3%) were in NYHA class IIIFigure 3 Cumulative Event Curve for All-Cause Mortality or Major St
Event rates were calculated with Kaplan-Meier methods. Brackets indicate 95% conﬁdenor IV, and at each subsequent follow-up, the majority of
patients were in NYHA class I or II (Fig. 4). Fewer than
15% of patients had no change in their functional status
from baseline to 1 month, 6 months, or 12 months (13.9%,
7.3%, and 6.3%, respectively). The proportion of patients
who were alive and had a worsening in functional status
following TAVR was <1% at any follow-up visit.
Echocardiographic ﬁndings. Serial echocardiographic
ﬁndings by the core laboratory are in Table 5. The mean
aortic valve gradient was reduced from 47.3  14.6 mm Hg
at baseline to 8.9  4.1 mm Hg (D 39.8  14.8 mm Hg;
p < 0.0001 for paired echocardiograms), and the effective
oriﬁce area was signiﬁcantly increased from 0.7  0.2 cm2 to
1.9 0.5 cm2 at the 12-month follow-up (D 1.2 0.6 mmHg;
p < 0.0001 for paired echocardiograms) (Fig. 5). The
left ventricular ejection fraction was 54.5%  14.4% at
baseline and increased to 57.3%  11.6% at the 12-month
follow-up. The frequencies of total, paravalvular, and cen-
tral aortic regurgitation are presented in Table 5. Trans-
valvular regurgitation was uncommon at any time point
after CoreValve THV placement. The frequency of mod-
erate paravalvular aortic regurgitation was lower 12 months
after self-expanding TAVR (4.2%) than at discharge
(9.7%; p ¼ 0.004 for paired analyses) (Fig. 6A). In patients
with moderate paravalvular aortic regurgitation at dis-
charge and paired echocardiograms at 12 months, 82.8%
showed an improvement of the moderate paravalvular
regurgitation (Fig. 6B). For patients with less than mod-
erate paravalvular regurgitation at discharge and paired
echocardiograms at 12 months, 2.9% worsened to mod-
erate paravalvular regurgitation. Late mortality was asso-
ciated with total severe aortic regurgitation at the time of
discharge (Fig. 7).roke
ce interval.
Figure 4 NYHA Classiﬁcation Over Time
Symptom status according to New York Heart Association (NYHA) class is shown
at baseline and at 30 days, 6 months, and 1 year among patients undergoing
attempted transcatheter aortic valve replacement.
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1978Discussion
Our main ﬁnding was that treatment of severe aortic
stenosis with the CoreValve self-expanding bioprosthesis
in patients deemed extreme risk for conventional surgery
reduced the frequency of all-cause mortality or major stroke
at 12 months compared with an OPG (26.0% vs. 43.0%;
p < 0.0001). This self-expanding aortic bioprosthesis pro-
vided sustained improvement in the aortic valve effectiveTable 5 Serial Echocardiography Findings in Patients Undergoing Co
Baseline Post-Procedural
n 481 456
Mean aortic gradient, mm Hg 47.3  14.6 9.6  4.4
Effective oriﬁce area, cm2 0.73  0.23 1.87  0.55
Total aortic regurgitation, n 477 460
None 56 (11.7) 64 (13.9)
Trivial 174 (36.5) 174 (37.8)
Mild 205 (43.0) 162 (35.2)
Moderate 41 (8.6) 51 (11.1)
Severe 1 (0.2) 9 (2.0)
Paravalvular regurgitation, n 449
None d 83 (18.5)
Trivial d 161 (35.9)
Mild d 158 (35.2)
Moderate d 40 (8.9)
Severe d 7 (1.6)
Transvalvular regurgitation, n 445
None d 323 (72.6)
Trivial d 92 (20.7)
Mild d 25 (5.6)
Moderate d 4 (0.9)
Severe d 1 (0.2)
Values are n, mean  SD, or n (%).oriﬁce area, a reduction in the aortic valve gradient, and an
overall improvement in NYHA functional class.
Risk assessment. Patient selection for TAVR has relied
upon an interdisciplinary heart team who collectively
determine patient risk for aortic valve surgery (24,25). These
decisions are often based on subjective assessments that
incorporate factors beyond those captured in traditional
surgical risk assessment tools (26), such as STS-PROM (10)
or logistic EuroSCORE (27). In the current study, patients
were judged by the clinical site heart team to have a 50% or
greater risk for 30-day mortality or irreversible morbidity
with conventional SAVR, a risk that was conﬁrmed by a
national screening committee. Our detailed assessment of
surgical comorbidities, frailty, and disability provided further
objective evidence of poor suitability for surgery in these
extreme-risk patients. STS-deﬁned severe pulmonary dis-
ease was present in nearly 25% of patients, severe comor-
bidity using the Charlson index was present in nearly 60%
of patients, slow gait speed or wheelchair bound was present
in approximately 85% of patients, and 27.6% of patients
did not live independently.
Mortality and major stroke. The 30-day mortality rate of
8.4% in our study is comparable to the 30-day mortality
rate of 6.7% in inoperable patients treated with the trans-
femoral SAPIEN (Edwards Lifesciences, Irvine, California)
THV in the Transcatheter Valve Therapy Registries (28),
considering the extreme comorbidity, frailty, and disability
proﬁled in our patients. The 12-month mortality rate of
24.3% in this study is also comparable to the 12-month
mortality of 30.7% in the PARTNER B trial (4). More-
over, the incidence of major stroke at 30 days was lowerreValve Transcatheter Heart Valve Implantation
Discharge 1 Month 6 Months 12 Months
443 418 364 330
9.6  4.3 8.7  4.2 9.1  3.9 8.9  4.1
1.80  0.52 1.86  0.56 1.88  0.55 1.88  0.54
450 419 367 329
53 (11.88) 38 (9.1) 73 (19.9) 70 (21.3)
155 (40.0) 137 (32.7) 123 (33.5) 134 (40.7)
180 (40.0) 180 (43.0) 134 (36.5) 104 (31.6)
54 (12.0) 59 (14.1) 36 (9.8) 21 (6.4)
8 (1.8) 5 (1.2) 1 (0.3) 0
440 412 364 327
70 (15.9) 64 (15.5) 89 (24.5) 95 (39.1)
145 (33.0) 130 (31.6) 124 (34.1) 123 (37.6)
178 (40.5) 171 (41.5) 120 (33.0) 95 (29.1)
40 (9.1) 45 (10.9) 31 (8.5) 14 (4.3)
7 (1.6) 2 (0.5) 0 0
439 411 362 325
309 (70.4) 266 (64.7) 263 (72.7) 238 (73.2)
103 (23.5) 107 (26.0) 74 (20.4) 64 (19.7)
21 (4.8) 32 (7.8) 23 (6.4) 23 (7.1)
5 (1.1) 6 (1.5) 2 (0.6) 0
1 (0.2) 0 0 0
Figure 5 Changes in Mean Aortic Valve Gradient Over Time
The mean aortic valve gradient is displayed in mm Hg (red) and the mean effective oriﬁce area is displayed in cm2 (blue) at each follow-up.
Figure 6
Changes in Paravalvular Regurgitation Over Time and
Regurgitation Grades Over Time in Patients With
Moderate Paravalvular Regurgitation at Discharge
(A) The percentage of patients by degree of paravalvular aortic regurgitation at
each follow-up interval. (B) Echocardiograms were presented for 29 patients with
paired echocardiographic studies at discharge and 12-month follow-up.
TAVR ¼ transcatheter aortic valve replacement.
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1979(2.3%) than that reported in the PARTNER B trial (5.0%)
(4). This may be attributable to the lower proﬁle of the
CoreValve device (18-F) compared with the 22-F and 24-F
diameter SAPIEN devices (4), resulting in less trauma
during advancement of the THV around the aortic arch.
Aortic regurgitation. Moderate or severe paravalvular
regurgitation occurs in 9% to 16% of patients after TAVR,
depending on the time point of measurement, implantation
depth, valve sizing, extent of calciﬁcation, and clinical site
versus core laboratory review (29–31). The presence of
moderate or severe aortic regurgitation post-TAVR increased
mortality at 30 days and 1 year in several studies (29–31). The
results of our study demonstrated a relatively low rate of
moderate or severe paravalvular aortic valve regurgitation
(4.3%) identiﬁed by the core laboratory 1 year after Core-
Valve THV placement. The severity of moderate aortic
regurgitation improved over time in patients with paired
discharge and 1-year echocardiograms (Fig. 6B), potentially
attributable to the use of pre–computed tomography assess-
ment of aortic annular diameter prior to the procedure
(32,33), higher placement of the THV within the aortic
annulus, and use of post-dilation in the presence of signiﬁ-
cant paravalvular regurgitation during the procedure. The
improvement of moderate regurgitation in our patients
suggests that there is ongoing remodeling of the annular-
bioprosthesis interface with the self-expanding device.
Conduction system disturbances. Conduction system
disturbances may occur following CoreValve TAVR, due to
mechanical trauma applied by the extended frame length
to the membranous septum in the region of the atrioven-
tricular conduction system and left bundle branch (34,35).
Accordingly, the need for a permanent pacemaker placement
after CoreValve implantation has been reported from 25.8%
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Figure 7 Mortality Over Time by Grade of Paravalvular Aortic Regurgitation
There was a signiﬁcant relationship in the presence of severe paravalvular regurgitation at discharge and late mortality.
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1980to 33.0% (36,37). Although placement of a permanent pace-
maker does not seem to affect late mortality (38), we used “best
practices” to reduce the occurrence of conduction disturbances
during TAVR, including smaller pre-dilation balloons, valve
sizing based on computed tomography, and higher positioning
of the CoreValve THV with avoidance of the conduction
system (39,40). In the current study, the rate of permanent
pacemaker implantation was 21.6% at 30 days post-procedure.
Lower permanent pacemaker rates may be attributable to the
revised implantation methods that were part of this study.
Study limitations. The primary endpoint of the study was
compared with an OPG of medically treated patients rather
than a randomized study with medical therapy due to the
lack of continued clinical equipoise with TAVR and medical
therapy (4). Only severe aortic regurgitation was associated
with late mortality in this study, but the small number
of patients with moderate aortic regurgitation precludes
any deﬁnitive conclusions about the relationship between
moderate aortic regurgitation and late mortality with the
self-expanding THV. TAVR was a new procedure for all
of the clinical sites participating in this trial, and better
procedural outcomes may be expected with more experience
in patient selection and operator technique.
Conclusions
Based on the ﬁndings of this study, TAVR using the
self-expanding CoreValve THV should be considered analternative to medical therapy in patients with severe aortic
stenosis who are deemed extreme risk for surgery.
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